A blood test that calculates the amount of cfDNA (cell-free DNA) in the bloodstream—commonly known a liquid biopsy—associates with how patients progress following they are identified with GBM (glioblastoma), which is the deadliest and most widespread primary brain tumor in adults. During the new study, scientists from the ACC (Abramson Cancer Center) of the University of Pennsylvania showed that patients having a higher concentration of cfDNA have short progression-free survival compared to patients having less cfDNA and that cfDNA increases in patients either during or just prior to their disease progresses.
The research team also correlated genetic sequencing of firm tissue biopsies in GBM alongside with the liquid biopsies and discovered that while biopsies discovered genetic mutations in over half of patients, none of those mutations overlaid, indicating liquid biopsy might provide complementary data regarding the genetic or molecular makeup of each tumor. The research findings were published in Clinical Cancer Research, which is a journal of the AACR (American Association for Cancer Research). Erica L. Carpenter—Study’s Senior Author and Assistant Professor of Medicine at the University of Pennsylvania—said, “Physicians have started to use liquid biopsies more normally to track definite cancers, mainly lung cancer, in the last couple of years as research showed their efficiency in other disease sites.”
On a related note, recently, researchers developed a novel method to identify cancerous DNA in the blood of people with lung cancer. A novel technique of determining the series of molecules in DNA can be utilized to find out small parts of cancerous genetic material in the blood samples of lung cancer patients by a high degree of accuracy, as per to new research. The study was published in the journal Annals of Oncology. The outcomes from analyses of “liquid biopsies” in people having NSCLC (non-small cell lung cancer) showed that it is possible to recognize the genetic alternatives that are either driving cancer or making it defiant to treatment.
Being an experienced member of the team with an experience of 6 years, Nancy Byrd is a dynamic part of this organization. Having the intent to bring the latest information and innovations &invention from the Health field to the ordinary public in an understandable way got Nancy into the writing world. She writes about the numerous official approvals, new developments, drug discoveries, health programs & initiatives, and much more. Being a reading freak, Nancy, in spare time, reads book of genres suspense, inspirational, or thriller.